Measurement of Intervention Strategies for the Treatment and (Prevention?) of Mycoplasmal Pneumonia using a Model System Eileen L. Thacker, DVM, PhD, DACVM.

Slides:



Advertisements
Similar presentations
Pneumonia MICS3 Data Analysis and Report Writing.
Advertisements

The Critical Challenge of Antibiotic Resistance: Are Wastewater Treatment Plants a Concern? Kourtney Brown 1, Stefan Walston 2, Channah Rock 2, & Jean.
“Suis-cide” Disease and Nursery Production Kevin J. Vilaca, B.Sc., M.Sc., DVM Maitland Swine Services Ontario, Canada.
The Resistance Problem PRSP = Penicillin Resistant Strep. pneumoniae QRSP = Quinolone Resistant Strep. pneumoniae MRSA = Methicillin Resistant Staph.
Of Mice, Men and Cell Cultures: Cryptosporidium parvum (Genotype 2) Infectivity.
ARIAtlas.org. Pneumonia is responsible for nearly 20 percent of child deaths globally. Source: ARIAtlas.org, World Lung Foundation 2010.
Diagnostic Microbiology and Immunology
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
Use of antibiotics. Antibiotic use Antimicrobials are the 2 nd most common drugs prescribed by office based physicians In USA1992: 110 million oral antimicrobial.
Interactions Between M. hyopneumoniae and Other Pathogens
Contagious Caprine Pleuropneumonia Mycoplasma capricolum subspecies capripneumoniae.
Chapter 10: Restricting antibiotic use and optimizing dosing.
Mycoplasma hyopneumoniae Associated Respiratory Disease on the Farm Brad Thacker Iowa State University.
Laboratory Training for Field Epidemiologists Strengthening Laboratory and Epidemiology Collaboration Introduction May 2007.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.
Mycoplasmal pneumonia in Swine
Education Level Poverty Access to health care Access to bug nets Tropical/subtropical temperatures Malaria infected female mosquitos Access to antimalarial.
Swine Influenza (SI), Flu Dr. Zuhair Bani Ismail Jordan University of Science and Technology.
Current Trends in Presentation of Disease Associated with M. hyopneumoniae Monte B. McCaw DVM PhD Farm Animal Health and Resource Management Dept. NCSU.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Do Physicians Find Our AST Reports As Confusing As We Do? Louis B. Rice, M.D. Louis Stokes Cleveland VA Medical Center and Case Western Reserve University.
Understanding the Clinical Microbiology Laboratory Carol R. Quinter Ph.D. January, 2007.
Bacteremia and CRBSI as Labeled BSI Indications: A Regulatory History Alfred Sorbello, DO Medical Officer CDER/Division of Anti-Infective Drug Products.
Canine Influenza. Overview Organism History Epidemiology Transmission Disease in Humans Disease in Animals Prevention and Control Center for Food Security.
Aims of study This surveillance study was performed to determine the in vitro activity of ciprofloxacin against clinical isolates of Escherichia coli and.
Faster, better, cheaper (PRRSV) surveillance using oral fluid-based sampling Jeff Zimmerman DVM PhD Iowa State University Ames, Iowa.
"Clinical Trials and Clinical Endpoints" James R. Bradford, DVM, Dipl. ABVP Pharmacia Animal Health.
Evaluation of the efficacy of one dose of autogenous MJPRRS vaccine in nursery pigs Dr. Mark Wagner, DVM Fairmont Veterinary Clinic Fairmont, MN.
Persistence and Prevalence of MRSA on Ocular Surface following Primary MSSA/MRSA Infections Darlene Miller, DHSc, MPH, CIC David Almeida, MD, PhD Eduardo.
Laboratory Training for Field Epidemiologists Cultivation of parasites Investigation strategies and methods May 2007.
Pathological Diagnosis of Mycoplasmosis in Swine
Dentistry By: Glen’Asia Cox. The Problem…  Despite its long clinical success, a current issue or challenge in this potential career field that I’ve discovered.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
1 Antibiotic Resistance: An Update Janice Soreth, M.D. Director Division of Anti-Infective Drug Products February 20, 2002.
Microbes and disease Microbes and Disease: Establishing a Connection History and Relevance of Koch's Postulates And The Germ Theory of Infectious Disease.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
Phage therapy for the treatment for urinary tract infection: Results of in-vitro screenings and in-vivo application using commercially available bacteriophage.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
Evaluation of Real-time PCR for Atypical pneumonia Wantana Paveenkittiporn 1 *, Anusak Kerdsin 2, Apimon Jirapongsathorn 1, Kanthana Boonsang 1, Saowalak.
Outcomes of Carbapenem-Resistant K. pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies Gopi Patel, MD; Shirish Huprikar, MD;
Topic: Airborne infection: Characteristics and laboratory diagnosis of tuberculosis, leprosy, actinomycosis - Tuberculosis, leprosy, actinomycosis in children.
Nitroxoline does not result in microbiological eradication in geriatric patients with lower urinary tract infection: a prospective cohort study C. Forstner1,2*,,
Other Pathogenic Gram-Negative Rods
Figure 1. Rate of antimicrobial resistance in S. pneumoniae
Surya Chitra, PhD MBA Director Biostatistics Endo Health Solutions
Use of antibiotics.
Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.
Topic: S e intestinal infections: characteristics and laboratory diagnosis of diseases in the title of s x s Escherichia coli, Yersinia intestinal s E,
The Immune and Lymphatic Systems
Background Goals Methods Conclusions Results
This is an archived document.
R. Leclercq  Clinical Microbiology and Infection 
Microbes and Disease.
Pseudomonas Lung Infections in Cystic Fibrosis
Nontuberculous Mycobacterial Lung Disease
Rates of Improvement (in percentage points) for Heart Attack Care Treatments Since Measure Inception,
Observational Studies vs. Randomized Controlled Trials (RCT)
Non-antibiotic strategies for sepsis
Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli  R.A. Hickman, D. Hughes,
ANTIBIOTIC RESISTANCE
LATIN-AMERICAN MULTICENTRE STUDY ON ANTIBIOTIC RESISTANCE OF S
G. Höffken  Clinical Microbiology and Infection 
Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections  P.S. Hicks, B.
Isolation rate, T-serotyping and susceptibility to antibiotics of Group A Streptococcus from pediatric infections in Athens*   M. Kanellopoulou, A. Makri,
J. Garau  Clinical Microbiology and Infection 
Role of communicable disease control measures in affecting the spread of resistant pneumococci: the Swedish model  Karl Ekdahl, Otto Cars  Clinical Microbiology.
Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents    Clinical Microbiology and Infection  Volume.
Presentation transcript:

Measurement of Intervention Strategies for the Treatment and (Prevention?) of Mycoplasmal Pneumonia using a Model System Eileen L. Thacker, DVM, PhD, DACVM Iowa State University

Measurement of Intervention Strategies Goals and measurements:Goals and measurements: –productivity –clinical disease - coughing –percentage of pneumonia – lung lesions macroscopicmacroscopic microscopicmicroscopic –number of organisms reductionreduction sterilizationsterilization

This will determine what parameters need to be measured

What do we need to measure for antibiotics? Production parametersProduction parameters Clinical diseaseClinical disease Percentage of pneumoniaPercentage of pneumonia Number of organismsNumber of organisms

M. hyopneumoniae Isolation of the organismIsolation of the organism –Difficult –Limited number of field isolates available – virulence? Growth of the organismsGrowth of the organisms Long term effect of culture on organismLong term effect of culture on organism

First Step Determine in vitro susceptibilities and the MICDetermine in vitro susceptibilities and the MIC –field isolates Culture techniquesCulture techniques In vitro culture techniquesIn vitro culture techniques Care must be taken when interpreting in relation to results in the pigCare must be taken when interpreting in relation to results in the pig

In the Pig - Alone Pure infectionPure infection –strain 232 –others??? ModelModel –culture vs lung homogenate Production parametersProduction parameters Percentage of pneumonia – consistencyPercentage of pneumonia – consistency Number of organisms – what assays?Number of organisms – what assays?

Field Trials What mimics “the real world”What mimics “the real world” –Variation between systems –What pathogens –Identification of pathogens –Role of other pathogens What do we measure?What do we measure? Antibiotic effect on secondary pathogensAntibiotic effect on secondary pathogens

Model Field Trials Co-infections?Co-infections? –M. hyopneumoniae –P. multocida –APP –PRRSV –SIV –Circo –etc. – where do we stop?

Answers Difficult to determineDifficult to determine Best needs and interests of the industryBest needs and interests of the industry –what does M. hyopneumoniae on the label mean? Can be doneCan be done –CTC has been shown if administered prior to challenge to reduce number of organisms –unsuccessful with others

Questions - Many